This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Web of Science (1) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Lok, C. E. Articles by Stanley, K. Search for Related Content PubMed PubMed Citation Articles by Lok, C. E. Articles by Stanley, K. Social Bookmarking                         What's this?

Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study

Nephrology, University Health Network-Toronto General Hospital, Toronto, Canada, charmaine.lok{at}uhn.on.ca

Michael Allon

Nephrology, University of Alabama, Birmingham, AL, USA

Sandra Donnelly

Nephrology, St. Michael's Hospital, Toronto, ON Canada

Marc Dorval

Nephrology, Dr. Georges, L. Dumont Regional Hospital, Moncton, NB, Canada

Brenda Hemmelgarn

Nephrology, Foothills Hospital, Calgary, AB, Canada

Louise Moist

Nephrology, University of Western Ontario, London, ON Canada

Matthew J. Oliver

Nephrology, Sunnybrook Health Sciences Centre, Toronto, Canada

Marcello Tonelli

Nephrology, University of Alberta, Edmonton, AB, Canada

Kenneth Stanley

Harvard School of Public Health, Boston, MA, USA

Background Arteriovenous grafts (AVG) are the predominant form of permanent vascular access used among hemodialysis (HD) patients in North America but suffer from high intervention and complication rates associated with vascular stenosis. The fish oil inhibition of stenosis in hemodialysis grafts (FISH) study evaluates the efficacy of fish oil in improving HD graft patency.

Methods This study is a multi-center, randomized, double blind placebo-controlled clinical trial of 232 chronic HD patients who require a new graft access. Participants are randomized to fish oil versus placebo post-operatively. The primary endpoint is the proportion of AVG with loss of native patency within 12 months of creation. Secondary endpoints are aimed to determine the effect of fish oil on factors that may promote stenosis and thrombosis. Cumulative patency rates, survival analysis, and analysis of inflammatory markers and adverse events will provide a better understanding of the potential effect of fish oil on a patient's vascular access and cardiovascular system. The FISH study is registered at current controlled trials (www.controlled-trials.com) ISRCTN: 15838383.

Results Details of the study protocol are described including mechanisms of reducing bias through randomization and double blinding, sample size determination, evaluation of patient adherence, access monitoring, and the safety of using fish oil. The main challenges of designing and implementing this study, including using a natural supplement as an intervention in modern medical practice and recruitment of graft recipients in the `fistula first' environment are discussed. Conclusion This is the first large, multicenter, randomized controlled trial of a natural supplement in preventing HD graft stenosis and thrombosis. Clinical Trials 2007; 4: 357—367. http://ctj.sagepub.com

Clinical Trials, Vol. 4, No. 4, 357-367 (2007)
DOI: 10.1177/1740774507081218


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?